abiraterone + ADT + docetaxel

ADT-Northwestern University-metastatic hormone sensitive prostate cancer refers to a therapeutic regimen being evaluated in a Phase II randomized clinical trial led by Northwestern University. The trial investigates the efficacy of 'triplet therapy'—combining Androgen Deprivation Therapy (ADT), abiraterone acetate, and docetaxel—compared to 'doublet therapy' (ADT plus abiraterone) in patients with low-volume metastatic hormone-sensitive prostate cancer (mHSPC). ADT serves as the backbone of treatment by reducing testicular androgen production. Abiraterone acetate is a small molecule inhibitor of the CYP17 enzyme, which blocks androgen synthesis in the adrenal glands and tumor cells. Docetaxel is a taxane chemotherapy agent that stabilizes microtubules, thereby inhibiting cell division and inducing apoptosis. The primary objective of this Northwestern-led study is to determine if the addition of docetaxel to the ADT-abiraterone doublet improves radiographic progression-free survival in this specific low-volume disease population.

Other names

ADT-Northwestern University-metastatic hormone sensitive prostate cancertriplet therapyADT + abiraterone + docetaxelabiraterone acetate + ADT + docetaxel